Black Diamond Therapeutics (BDTX)
(Real Time Quote from BATS)
$5.09 USD
+0.08 (1.60%)
Updated Apr 24, 2024 01:14 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BDTX 5.09 +0.08(1.60%)
Will BDTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDTX
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93%
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Other News for BDTX
12 Health Care Stocks Moving In Tuesday's After-Market Session
Black Diamond Therapeutics Announces Changes to Board of Directors
Black Diamond Therapeutics announces changes to board of directors
Black Diamond Therapeutics Revamps Board Leadership
Black Diamond Therapeutics (BDTX) Gets a Buy from Piper Sandler